What is NAD+ and How Does it Work?
A complete research guide to nicotinamide adenine dinucleotide — the coenzyme at the centre of cellular energy, DNA repair and longevity research.
NAD+ (Nicotinamide Adenine Dinucleotide) is one of the most fundamental molecules in cellular biology. Present in every living cell, it sits at the intersection of energy metabolism, DNA repair, and cellular senescence research — making it a critical reagent for longevity and bioenergetics studies. This guide explains what NAD+ is, how it works, and why it has become central to modern ageing research.
What is NAD+?
NAD+ is a coenzyme found in all living cells, playing an essential role in electron transfer reactions that power cellular metabolism. It exists in two primary forms: the oxidised form (NAD+) and the reduced form (NADH), cycling between the two as it accepts and donates electrons in metabolic reactions.
Beyond its classical role as an electron carrier, NAD+ functions as a substrate for several critical enzyme families — most notably Sirtuins (SIRT1-7) and PARP enzymes — that regulate gene expression, DNA repair, and cellular stress responses. It is this role that has made NAD+ such a compelling target in longevity and cellular ageing research.
How Does NAD+ Work?
Energy Metabolism
NAD+ is essential to the process of cellular respiration. In glycolysis and the citric acid cycle, NAD+ accepts electrons from metabolic intermediates, becoming NADH. This NADH is then used in the electron transport chain to generate ATP — the cell’s primary energy currency. Without sufficient NAD+, efficient ATP production cannot occur.
Sirtuin Activation
Sirtuins (SIRT1-7) are a family of NAD+-dependent deacetylase enzymes that regulate a wide range of biological processes including gene expression, inflammation, metabolic regulation, and DNA repair. Sirtuin activity is directly dependent on NAD+ availability — making NAD+ concentration a critical variable in sirtuin pathway research.
SIRT1 and SIRT3 are particularly well-studied in the context of metabolic regulation and mitochondrial biogenesis. SIRT6 has attracted significant attention for its role in DNA repair and telomere maintenance.
PARP Enzymes and DNA Repair
PARP (Poly ADP-ribose polymerase) enzymes use NAD+ as a substrate to detect and repair DNA strand breaks. When DNA damage occurs, PARP enzymes rapidly consume NAD+ to build poly-ADP-ribose chains that recruit DNA repair machinery. This consumption can significantly deplete cellular NAD+ levels under conditions of high DNA damage.
NAD+ and Cellular Senescence
A well-documented finding in ageing research is the progressive decline in cellular NAD+ levels with age. This decline is associated with reduced sirtuin activity, impaired mitochondrial function, and decreased capacity for DNA repair — all hallmarks of cellular senescence. Research into NAD+ repletion as a mechanism for modulating senescence pathways has been a major focus of longevity biology.
NAD+ vs NMN — What’s the Difference?
NMN (Nicotinamide Mononucleotide) is a precursor molecule that cells convert into NAD+. The distinction matters for research design:
| Property | NAD+ | NMN |
|---|---|---|
| Form | Active coenzyme | Biosynthetic precursor |
| Cellular Action | Direct | Requires conversion to NAD+ |
| Research Use | Direct pathway studies | Biosynthesis pathway studies |
| Sirtuin Activation | Direct substrate | Indirect (via NAD+) |
| PARP Substrate | Yes | No (indirect) |
For research requiring direct NAD+ pathway activity — sirtuin activation, PARP studies, or electron transport chain modelling — NAD+ is the appropriate reagent. NMN is better suited to research into the biosynthetic pathway itself.
Key Research Applications
- Longevity and Senescence Research: NAD+ depletion models and repletion studies in cellular ageing frameworks.
- Mitochondrial Function: Studying the relationship between NAD+ availability and mitochondrial biogenesis and efficiency.
- DNA Repair Pathways: PARP enzyme activity and its consumption of NAD+ under genotoxic stress.
- Sirtuin Biology: NAD+-dependent regulation of gene expression, inflammation and metabolic homeostasis.
- Metabolic Research: Role of NAD+ in glycolytic efficiency and the TCA cycle.
Compound Profile
| Property | Detail |
|---|---|
| Chemical name | Nicotinamide adenine dinucleotide (oxidised form) |
| Molecular formula | C21H27N7O14P2 |
| Molecular weight | 663.4 g/mol |
| CAS number | 53-84-9 |
| Biosynthesis routes | De novo from tryptophan; Preiss–Handler pathway from nicotinic acid; salvage pathway from nicotinamide via NAMPT and NMN |
| Main NAD+ consumers | Sirtuins, PARPs, CD38/CD157 and SARM1 |
| Related precursors | Nicotinamide riboside (NR, CAS 1341-23-7); nicotinamide mononucleotide (NMN, CAS 1094-61-7) |
Key Published Research
- NAD+ and ageing (2015): A landmark review linked falling NAD+ to metabolic decline and neurodegeneration, framing NAD+ repletion as a research strategy.1
- Why NAD+ falls with age (2016): Expression of the NAD+-consuming enzyme CD38 rose with age in mice and drove NAD+ decline and mitochondrial dysfunction through a SIRT3-dependent mechanism.2
- Precursor evidence (2018): A review of in-vivo studies compared NR, NMN and other NAD+-boosting strategies and noted that exogenous NAD+ is largely broken down outside cells before uptake.3
- NMN in humans (2021): In a 10-week randomised trial in postmenopausal women with prediabetes, NMN increased muscle insulin sensitivity.4
- NR in Parkinson’s disease (2022, 2023): The phase 1 NADPARK trial found NR raised brain NAD+ levels, and the NR-SAFE trial reported high-dose NR was well tolerated over four weeks.5,6
- Cellular roles (2021): A review set out how NAD+ metabolism links energy production, DNA repair, inflammation and senescence during ageing.7
Research Status (2026)
- NOPARK: The 400-participant phase 3 trial of NR in early Parkinson’s disease completed dosing in 2025; its results are one of the most anticipated readouts in the field.
- NMN regulation: In September 2025 the US FDA confirmed that NMN is not excluded from the definition of a dietary supplement, reversing its 2022 position.
- Direct NAD+ administration: Intravenous NAD+ offered by wellness clinics has not been evaluated in large controlled trials; most human evidence concerns oral precursors.
Evidence Quality & Limitations
NAD+ biology is well established, but translating it into interventions is not. Human precursor trials have mostly been small and short, with biomarker rather than clinical endpoints, and results vary between tissues. In cell and animal work, remember that extracellular NAD+ is rapidly converted to NMN, NR and nicotinamide, so observed effects may reflect these breakdown products rather than intact NAD+.
References
- Verdin E. NAD+ in aging, metabolism, and neurodegeneration. Science. 2015;350:1208–13. PubMed
- Camacho-Pereira J, et al. CD38 dictates age-related NAD decline and mitochondrial dysfunction through an SIRT3-dependent mechanism. Cell Metab. 2016;23:1127–39. PubMed
- Rajman L, et al. Therapeutic potential of NAD-boosting molecules: the in vivo evidence. Cell Metab. 2018;27:529–47. PubMed
- Yoshino M, et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science. 2021;372:1224–9. PubMed
- Brakedal B, et al. The NADPARK study: a randomized phase I trial of nicotinamide riboside supplementation in Parkinson’s disease. Cell Metab. 2022;34:396–407. PubMed
- Berven H, et al. NR-SAFE: a randomized, double-blind safety trial of high dose nicotinamide riboside in Parkinson’s disease. Nat Commun. 2023;14:7793. PubMed
- Covarrubias AJ, et al. NAD+ metabolism and its roles in cellular processes during ageing. Nat Rev Mol Cell Biol. 2021;22:119–41. PubMed
